Lexaria Bioscience Corp. Stockholders Equity

• Lexaria Bioscience Corp. showed a decrease of -62.8% in Stockholders Equity from 2024 to 2025.
• This data is from Lexaria Bioscience Corp.'s annual report (Form 10-K), filed with the SEC on November 28, 2025.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q3 2011: $2.39 million | Q1 2012: $2.55 million | Q2 2012: $2.32 million | Q3 2012: $2.39 million | Q4 2012: $2.42 million | Q1 2013: $2.31 million | Q2 2013: $2.26 million | Q3 2013: $2.23 million | Q4 2013: $2.10 million | Q1 2014: $2.03 million | Q2 2014: $3.73 million | Q3 2014: $3.55 million | Q4 2014: $1.42 million | Q1 2015: $1.14 million | Q2 2015: $1.15 million | Q4 2015: $463.8 thousand | Q1 2016: $265.0 thousand | Q2 2016: $120.7 thousand | Q4 2016: $806.7 thousand | Q1 2017: $691.2 thousand | Q2 2017: $3.26 million | Q3 2017: $2.77 million | Q3 2017: $2.77 million | Q4 2017: $2.40 million | Q1 2018: $2.77 million | Q2 2018: $2.64 million | Q3 2018: $2.39 million | Q4 2018: $3.41 million | Q1 2019: $3.77 million | Q2 2019: $3.32 million | Q4 2019: $2.62 million | Q1 2020: $1.92 million | Q2 2020: $3.20 million | Q3 2020: $2.48 million | Q4 2020: $1.82 million | Q1 2021: $11.70 million | Q2 2021: $10.27 million | Q3 2021: $13.06 million | Q4 2021: $11.47 million | Q1 2022: $11.22 million | Q2 2022: $9.18 million | Q4 2022: $6.26 million | Q1 2023: $4.97 million | Q2 2023: $4.40 million | Q4 2023: $3.74 million | Q1 2024: $6.52 million | Q2 2024: $10.12 million | Q4 2024: $9.77 million | Q1 2025: $7.14 million | Q2 2025: $5.55 million | Q3 2025: $2.99 million | Q4 2025: $4.91 million.
• Over the full 17 years of available data (2009 to 2025), Lexaria Bioscience Corp.'s Stockholders Equity has grown by 30.1%.
• Historical annual values: Fiscal year 2025: $2.99 million | Fiscal year 2024: $8.04 million | Fiscal year 2023: $3.04 million | Fiscal year 2022: $7.95 million | Fiscal year 2021: $13.27 million | Fiscal year 2020: $2.48 million | Fiscal year 2019: $2.49 million | Fiscal year 2018: $2.39 million | Fiscal year 2017: $2.77 million | Fiscal year 2016: $266.0 thousand | Fiscal year 2015: $772.4 thousand | Fiscal year 2014: $1.72 million | Fiscal year 2013: $2.10 million | Fiscal year 2012: $2.42 million | Fiscal year 2011: $2.66 million | Fiscal year 2010: $2.15 million | Fiscal year 2009: $2.30 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026